AA
TARO

AlphaCentric Advisors’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

AlphaCentric Advisors’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,500
Closed -$790K – 283
2023
Q1 		$790K Buy
32,500
+5,000
+18% +$146K 0.55% 65
2022
Q4 		$799K Buy
27,500
+3,000
+12% +$89K 0.79% 44
2022
Q3 		$735K Buy
+24,500
New +$845K 0.75% 43

Other funds holding TARO

KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

AlphaCentric Advisors's TARO Position: Q2 2023 in Review

AlphaCentric Advisors sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2023, closing a stake of 32,500 shares — an estimated $790K sold.

AlphaCentric Advisors first reported a position in TARO in Q3 2022 and held it in 3 quarters. The position peaked at $799K in Q4 2022. 71 funds tracked by Wall St. Rank hold TARO as of Q2 2023.

  • AlphaCentric Advisors reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 32,500 Taro Pharmaceutical Industries Ltd. shares in Q2 2023, an estimated $790K.
  • AlphaCentric Advisors first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2022 and held it in 3 quarters.
  • AlphaCentric Advisors's Taro Pharmaceutical Industries Ltd. position peaked at $799K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.